Abstract
Glucose encapsulated cadmium oxide nanoparticles (G-CdO NPs) were synthesized by a sol-gel method. An array of different physical methods was used to characterize G-CdO NPs, including ultra violet-visible spectroscopy (lambda(Max) - 275 nm), transmission electron microscopy (TEM; 17 +/- 1 nm), and zeta potential ( - 8.24 +/- 0.4 mV) analyses. The NPs were active against HeLa cells (IC50 - 31.58 mu g/mL) and Saos-2 cells (IC50 - 12.51 mu g/mL) by preventing glycation (early, 95%; late, 65%). G-CdO NPs were effective anti-glycating agents and were highly effective against advanced glycation end products in particular. Localization of G-CdO NPs in the mitochondria and nuclei of cells was confirmed by TEM. Reactive oxygen species generated in the treated cells (confirmed by 2',7'-dichlorofluorescin diacetate based assay) caused disintegration of mitochondrial cristae, disruption of the membrane integrity, and condensation and degradation of the nuclei. The LD50 of G-CdO NPs on Swiss Albino mice was 1.432 mg/kg of body weight. The results indicate the potential therapeutic value of G-CdO NPs.